The patient's BRCA2 carrier status, combined with the DPYD I560S variant, creates a complex oncological pharmacogenomic profile requiring careful treatment planning. The BRCA2 heterozygous variant confers approximately 45% lifetime breast cancer risk and 11-17% ovarian cancer risk, while the DPYD deficiency substantially increases toxicity risk from fluoropyrimidine-based chemotherapy regimens.
Critically, these two findings interact: if the patient were to develop a BRCA2-associated malignancy requiring chemotherapy, standard fluoropyrimidine protocols would be contraindicated without dose reduction of at least 50%.
Your blood is processed by state of the art machines that yield gigabytes of genomic, transcriptomic, epigenetic and proteomic data.
Our deterministic pipeline queries 12+ clinical databases and runs multi-model AI synthesis across 11 medical disciplines. No hallucination — every finding is database-verified.
Your physician receives a comprehensive clinical intelligence report with discipline-separated findings, evidence tiers, and a personalized treatment plan.
Helyra's clinical engine is built entirely on commercially-clean, peer-reviewed data sources. No non-commercial databases. No licensing risk. HIPAA and FDA compliant.
What makes it proprietary is the assembly: our contraindication logic, supplement knowledge base, variant registry, composite risk evaluator, and the deterministic skeleton builder that converts raw genomic data into structured clinical findings — without any LLM involvement in the safety-critical path.
Our wellness recommendation engine draws from a curated database of evidence-backed health interventions — each validated against PubMed literature and matched to the patient's specific molecular profile, symptoms, and blood panel. Personalized wellness guidance grounded in science, not trends.
